Barcelona-based Grifols said that the deal includes Novartis’ nucleic acid amplification techniques in addition to other in vitro diagnostic products & technology for transfusion medicine & immunology. Grifols is also nabbing a U.S. manufacturing plant and commercial offices in U.S., Switzerland & Hong Kong.
The acquisition is part of Grifols’ efforts to expands its global diagnostics business, beginning with the U.S.
“We initiated the process in the Bioscience area in 2003 with the acquisition of the ATC assets and continued with the Talecris transaction in 2011,” Grifols president and CEO Victor Grifols said in prepared remarks. “During the last 2 years the Diagnostic Division has been preparing for this step, especially in the immunohematology activities.”
* Corrected Dec. 15, 2016, to reflect accurate deal price. ↩